- Trials with a EudraCT protocol (5,062)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5,062 result(s) found for: Cells.
Displaying page 2 of 254.
EudraCT Number: 2018-002502-31 | Sponsor Protocol Number: RP-L102-0118 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemi... | |||||||||||||
Medical condition: Fanconi anemia (subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001929-27 | Sponsor Protocol Number: NK4AML | Start Date*: 2020-05-20 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’ | ||
Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003185-26 | Sponsor Protocol Number: CIK 2 | Start Date*: 2009-04-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation | |||||||||||||
Medical condition: Patients with haematologic malignancies (excluding CML) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005713-39 | Sponsor Protocol Number: 42970 | Start Date*: 2014-09-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000124-34 | Sponsor Protocol Number: PFO-CTC | Start Date*: 2013-03-27 |
Sponsor Name:PD Dr. Maria De Santis | ||
Full Title: Circulating Tumor cells in urothelial cancer patients relapsing after or refractory to platinum based first line chemotherapy | ||
Medical condition: Circulating tumor cells in urothelial cancer patients relapsing after or refractory to platinum based first line chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002446-21 | Sponsor Protocol Number: ARTROCELL | Start Date*: 2020-04-20 | |||||||||||
Sponsor Name:IBSAL (Instituto de Investigación Biomédica de Salamanca) | |||||||||||||
Full Title: Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal cells and against active control with hyaluronic acid in ... | |||||||||||||
Medical condition: Knee osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004110-10 | Sponsor Protocol Number: 2ABC | Start Date*: 2017-12-21 | ||||||||||||||||
Sponsor Name:Medical University of Warsaw | ||||||||||||||||||
Full Title: Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The t... | ||||||||||||||||||
Medical condition: Scar or cutis laxa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000411-91 | Sponsor Protocol Number: NKZellen-Version1.0 | Start Date*: 2013-02-13 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial | ||
Medical condition: relapsing-remitting multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000805-22 | Sponsor Protocol Number: A20175CI03 | Start Date*: 2021-09-28 |
Sponsor Name:Neuroplast BV | ||
Full Title: A multi-center, double-blind, randomized, placebo-controlled, delayed- start phase II/III study to assess the efficacy and safety of Neuro-Cells in (sub)acute spinal cord injury patients | ||
Medical condition: Traumatic Spinal cord injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006964-48 | Sponsor Protocol Number: 20040215 | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone | |||||||||||||
Medical condition: Giant Cell Tumor (GCT) of bone | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002222-12 | Sponsor Protocol Number: G1XCGD.02 | Start Date*: 2015-10-08 |
Sponsor Name:Genethon | ||
Full Title: A phase I/II, non-randomized, monocentric, open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-Linked Chronic Granulomatous Disease. | ||
Medical condition: Chronic Granulomatous Disease (CGD) is a rare inherited disorder (1/250,000) of the phagocytes characterized by the inability of phagocytes (monocytes and neutrophils) to produce reactive oxygen sp... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001335-31 | Sponsor Protocol Number: virus-specific_CD8_T-cells_001 | Start Date*: 2013-11-08 |
Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta | ||
Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation | ||
Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006480-23 | Sponsor Protocol Number: 10,176 | Start Date*: 2007-10-12 |
Sponsor Name:University Hospitals of Leicester | ||
Full Title: Autologous Bone Marrow-Derived Cells for Cardioprotection During Heart Surgery | ||
Medical condition: Improvement of cardioprotection during elective coronary artery bypass graft surgery using the patients own bone marrow cells. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018901-12 | Sponsor Protocol Number: ADPP-002ENM-DA-017 | Start Date*: 2010-10-20 |
Sponsor Name:Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism [...] | ||
Full Title: Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Program... | ||
Medical condition: To evaluate whether vitamin D supplementation in type 1 diabetic subjects significantly alters the proportion of regulatory T-cells of all circulating CD4 positive T-cells. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000578-31 | Sponsor Protocol Number: Rostock-Benralizumab-2018-1 | Start Date*: 2018-07-05 |
Sponsor Name:University Medicine Rostock | ||
Full Title: Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma | ||
Medical condition: Eosinophilic Asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000242-35 | Sponsor Protocol Number: G1XCGD.01 | Start Date*: 2013-01-10 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: A phase I/II, non randomized, multicenter, open-label study of autologous CD34+ cells transduced with the G1XCGD Lentiviral vector in patients with X-Linked Chronic Granulomatous Disease | |||||||||||||
Medical condition: X-linked Chronic Granulomatous Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001514-34 | Sponsor Protocol Number: ILNK15-01 | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study | |||||||||||||
Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004953-26 | Sponsor Protocol Number: BHS-TC13 | Start Date*: 2016-03-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
